Common Contracts
5 similar Warrant Agreement contracts by EPIRUS Biopharmaceuticals, Inc.
FOURTEEN22, INC. WARRANT TO PURCHASE PREFERRED STOCKWarrant Agreement • August 11th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, 5AM VENTURES III, L.P., with its principal office at 2200 Sand Hill Road, Suite 110, Menlo Park, CA 94025, or its assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from FOURTEEN22, INC., a Delaware corporation (the “Company”), that number of Exercise Shares (as defined below) as set forth herein, during the Exercise Period (as defined below). The aggregate number of Exercise Shares (as defined below) that Holder may purchase by exercising this Warrant is equal to the Warrant Percentage (as defined below) multiplied by the original principal amount of the Convertible Promissory Note dated December 1, 2011 between the Holder and the Company (the “Note”); provided however that such aggregate number is subject to adjustment upon a Special Conversion (as defined in the Company’s Certificate of Incorporation (the “Certificate”)) pursuant to Article IV, Section D(5)(l) of the Certificate. Capitalize
FOURTEEN22, INC. WARRANT TO PURCHASE PREFERRED STOCKWarrant Agreement • August 11th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
This Warrant is being issued pursuant to the terms of the Series A Preferred Stock and Warrant Purchase Agreement dated as of January 25, 2011, as amended, by and among the Company and the Purchasers listed on the Schedule of Purchasers attached thereto (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings given them in the Purchase Agreement.
FOURTEEN22, INC. WARRANT TO PURCHASE PREFERRED STOCKWarrant Agreement • August 11th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, 5AM CO-INVESTORS III, L.P., with its principal office at 2200 Sand Hill Road, Suite 110, Menlo Park, CA 94025, or its assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from FOURTEEN22, INC., a Delaware corporation (the “Company”), that number of Exercise Shares (as defined below) as set forth herein, during the Exercise Period (as defined below). The aggregate number of Exercise Shares (as defined below) that Holder may purchase by exercising this Warrant is equal to the Warrant Percentage (as defined below) multiplied by the original principal amount of the Convertible Promissory Note dated December 1, 2011 between the Holder and the Company (the “Note”); provided however that such aggregate number is subject to adjustment upon a Special Conversion (as defined in the Company’s Certificate of Incorporation (the “Certificate”)) pursuant to Article IV, Section D(5)(l) of the Certificate. Capita
FOURTEEN22, INC. WARRANT TO PURCHASE PREFERRED STOCKWarrant Agreement • August 11th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, DEE ATHWAL, with his principal address at 13 Sussex Place, Slough, Berkshire, SL1 1NH, United Kingdom, or his assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from FOURTEEN22, INC., a Delaware corporation (the “Company”), that number of Exercise Shares (as defined below) as set forth herein, during the Exercise Period (as defined below). The aggregate number of Exercise Shares (as defined below) that Holder may purchase by exercising this Warrant is equal to the Warrant Percentage (as defined below) multiplied by the original principal amount of the Convertible Promissory Note dated December 1, 2011 between the Holder and the Company (the “Note”); provided however that such aggregate number is subject to adjustment upon a Special Conversion (as defined in the Company’s Certificate of Incorporation (the “Certificate”)) pursuant to Article IV, Section D(5)(l) of the Certificate. Capitalized te
FOURTEEN22, INC. WARRANT TO PURCHASE PREFERRED STOCKWarrant Agreement • August 11th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
This Warrant is being issued pursuant to the terms of the Series A Preferred Stock and Warrant Purchase Agreement dated as of January 25, 2011, as amended, by and among the Company and the Purchasers listed on the Schedule of Purchasers attached thereto (the “Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings given them in the Purchase Agreement.
